drugset / Trial / NCT01094184
A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This open-label, multi-center study will evaluate the safety, tolerability and effect of bevacizumab (Avastin) in combination with taxane (paclitaxel/ docetaxel) monotherapy on disease progression, survival time and Karnofsky performance status in female participants with estrogen-, progesterone- and human epidermal growth factor receptor 2 (HER2)-negative (triple-negative) breast cancer.
Timeline
- Start
- 2010-03
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Docetaxel | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |